Schlieren, Switzerland
CUTISS AG, a pioneering force in BIOTECHNOLOGY and HEALTH CARE, is redefining skin surgery with its innovative skin tissue therapeutics. Established in 2017 as a spin-off from the University of Zurich (UZH) and University Children’s Hospital, this Swiss firm is headquartered at the Bio-Technopark in Zurich.
At the core of CUTISS AG's offerings is denovoSkin™, a first-in-class, bioengineered, personalized skin tissue therapy, currently in Phase 3 clinical trials in the EU. With Orphan Drug Designation from Swissmedic, the EMA, and the US FDA, it aims to revolutionize treatment for severe burns and other indications. In parallel, the company is developing the world's first machine for automated skin tissue bioengineering, enhancing scalability and cost-efficiency.
Having raised over $90 million, with a recent €57.90M Series C investment on 10 September 2025 from investors like Swisspreneur and Rode Kruis Ziekenhuis, CUTISS AG showcases robust growth potential, verified by its recognition in the Top 100 Swiss Startup Award 2020.
